Korea National Enterprise for Clinical Trials & Quintiles Partner to Advance Clinical Research Education
SEOUL, South Korea–(BUSINESS WIRE)–The growth of high-quality clinical research in South Korea, one of
Asia’s fastest-growing countries for biopharmaceutical
development, is being boosted through a new partnership
between the Korea
National Enterprise for Clinical Trials (KoNECT)
and Quintiles,
the world’s largest biopharmaceutical services company.
“With KoNECT we can further
enhance the already high clinical research standards that exist here and
expand its clinical research capacity.”
KoNECT and Quintiles have signed a memorandum of understanding to
collaborate in producing educational events involving investigators,
local and multi-national biopharmaceutical companies and relevant
government officials.
“This MOU is a further indication of Quintiles’ long-standing commitment
to South Korea, where we first opened an office 11 years ago,” said
MiSook Hyun, head of Quintiles’
Clinical Operations in South Korea. “With KoNECT we can further
enhance the already high clinical research standards that exist here and
expand its clinical research capacity.”
KoNECT and Quintiles anticipate working together on educational events
beginning this summer.
“We are very proud to be working with Quintiles, a recognized leader in
advancing clinical research and raising professionalism not only in
Korea but globally,” said KoNECT President Sang-Goo Shin, M.D., Ph.D.
“Together we hope to improve clinical research expertise and build a
support infrastructure in Korea that’s second to none.”
Anand Tharmaratnam, M.D., Quintiles Senior Vice President and Head, Asia
Markets, said: “This collaboration is part of Quintiles’ efforts
across Asia-Pacific to advance
high-quality clinical research in support of patients who are
involved in trials to develop new medicines.”
About KoNECT
Established in 2007 with the support of the South Korean government,
academic institutions and life-science industries, KoNECT provides
clinical research resources, training and support. KoNECT’s vision is to
establish an advanced clinical trial infrastructure and develop the
nation’s biopharmaceutical industry to serve as an international hub for
clinical trials.
About Quintiles
Quintiles is the only fully integrated biopharmaceutical services
company offering clinical, commercial, consulting and capital solutions
worldwide. The Quintiles network of more than 20,000 engaged
professionals in 60 countries around the globe works with an unwavering
commitment to patients, safety and ethics. Quintiles helps
biopharmaceutical companies navigate risk and seize opportunities in an
environment where change is constant. For more information, please visit www.quintiles.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6738961lang=en
Article source: Read More
Related posts:
- North Korea threatens to fire at South Korea
- S. Korea will punish 10 diplomats over China scandal
- North Korea proposes talks on 4 people’s defection
- National Education Conference on Assessment and Year 2 of the 2010 Secondary Education Curriculum at the Historic Landmark Manila Hotel on April 6-8, 2011
- Research and Markets: Clinical Virology: An Oxymoron or a Useful Tool?
